Core Viewpoint - Recent phase II clinical research published by Chinese researchers in The Lancet shows significant progress in CAR-T therapy for malignant solid tumors, demonstrating a notable extension in progression-free survival for late-stage cancer patients compared to standard therapies [1] Group 1: CAR-T Therapy Overview - CAR-T therapy is a novel immunotherapy that involves isolating T lymphocytes from patients and genetically engineering them to recognize and specifically kill tumor cells [1] - Currently, CAR-T therapy is primarily used for the treatment of certain hematological malignancies [1] Group 2: Clinical Research Findings - The study indicates that CAR-T therapy significantly prolongs progression-free survival in late-stage cancer patients when compared to standard treatment options [1]